Theravance Biopharma, Mylan Reach Settlement Over Inhalation Drug Yupelri
By Sabela Ojea
Theravance Biopharma, Mylan Ireland and Mylan Specialty have entered into a settlement agreement with Teva Pharmaceutical Industries over their Yupelri inhalation drug, according to a Securities and Exchange Commission filing.
The biopharmaceutical company on Monday said the parties agreed to grant Teva a royalty-free, non-exclusive, non-transferable license to manufacture and market Teva's generic version of Yupelri in the U.S. on or after the licensed launch date of April 23, 2039.
The settlement is subject to review by the Justice Department and the Federal Trade Commission.
The companies didn't disclose financial details on the settlement.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 30, 2023 18:50 ET (22:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
How the Tokyo Stock Exchange Is Pushing for Better Capital Allocation
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting